Désirée E S Larenas-Linnemann1, Claudio A S Parisi2, Carla Ritchie3, Ricardo Cardona-Villa4, Ivan Cherrez-Ojeda5, Annia Cherrez6,7, Luis Felipe Ensina8, Elizabeth Garcia9, Iris V Medina10, Mónica Rodríguez-González11, Jorge Mario Sánchez Caraballo4. 1. Research Unit, Medica Sur Hospital and Clinical Foundation, Torre 2, cons.602, Puente de Piedra 150, Col. Toriello Guerra, Del. Tlalpan, 14050, México, D.F, Mexico. Marlar1@prodigy.net.mx. 2. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 3. Hospital Italiano, Buenos Aires, Argentina. 4. Grupo de Alergología Clínica y Expermiental, IPS Universitaria, Universidad de Antioquia, Medellín, Colombia. 5. Espiritu Santo University (UEES), Samborondon, Ecuador. 6. Respiralab Research Group, Guayaquil, Ecuador. 7. Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany. 8. Federal University of São Paulo, Hospital Sírio-Libanês, São Paulo, Brazil. 9. Fundación Santa Fe de Bogotá - Facultad de Medicina, Universidad de Los Andes, Bogotá, Colombia. 10. Centro Médico Vitae, Buenos Aires, Argentina. 11. Private Practice, Mexico City, Mexico.
Abstract
PURPOSE OF REVIEW: Since omalizumab has been approved for urticaria, numerous randomized and real-life observational trials have been published. We reviewed the period January 2017-February 2018. RECENT FINDINGS: Omalizumab is effective for the control of urticaria recalcitrant to antihistamines in different populations globally. The ratio of total serum IgE 4-week/baseline ≥2 can predict response with a high likelihood. In observational real-life trials, doses have been adjusted on an individual basis: in some populations, up to two-thirds of the patients can be controlled with 150 mg/month; however, others are still not controlled with 300 mg/month. In these, 150 mg bimonthly could be tried, before up-dosing to 450 mg/month. On the long run (up to 3 years) omalizumab kept its efficacy. In many patients, dosing intervals could be augmented (6-8 weeks, some even more). After a 12-month treatment, about 20% showed long-term remission without relapse. Some biomarkers are being detected. Adjusting omalizumab doses in urticaria patients could enhance efficacy (shortening dosing interval and/or augmenting dose) and save costs (after 12 months: extending dosing interval and/or reducing dose).
PURPOSE OF REVIEW: Since omalizumab has been approved for urticaria, numerous randomized and real-life observational trials have been published. We reviewed the period January 2017-February 2018. RECENT FINDINGS:Omalizumab is effective for the control of urticaria recalcitrant to antihistamines in different populations globally. The ratio of total serum IgE 4-week/baseline ≥2 can predict response with a high likelihood. In observational real-life trials, doses have been adjusted on an individual basis: in some populations, up to two-thirds of the patients can be controlled with 150 mg/month; however, others are still not controlled with 300 mg/month. In these, 150 mg bimonthly could be tried, before up-dosing to 450 mg/month. On the long run (up to 3 years) omalizumab kept its efficacy. In many patients, dosing intervals could be augmented (6-8 weeks, some even more). After a 12-month treatment, about 20% showed long-term remission without relapse. Some biomarkers are being detected. Adjusting omalizumab doses in urticariapatients could enhance efficacy (shortening dosing interval and/or augmenting dose) and save costs (after 12 months: extending dosing interval and/or reducing dose).
Authors: Janine Gericke; Martin Metz; Tatevik Ohanyan; Karsten Weller; Sabine Altrichter; Per Stahl Skov; Sidsel Falkencrone; Janko Brand; Arno Kromminga; Tomasz Hawro; Martin K Church; Marcus Maurer Journal: J Allergy Clin Immunol Date: 2016-11-09 Impact factor: 10.793
Authors: Marcus Maurer; Allen Kaplan; Karin Rosén; Michael Holden; Ahmar Iqbal; Benjamin L Trzaskoma; Ming Yang; Thomas B Casale Journal: J Allergy Clin Immunol Date: 2017-11-10 Impact factor: 10.793
Authors: S F Thomsen; E C Pritzier; C D Anderson; N Vaugelade-Baust; R Dodge; A-K Dahlborn; C Vestergaard Journal: J Eur Acad Dermatol Venereol Date: 2017-04-03 Impact factor: 6.166
Authors: Gustavo Deza; Marta Bertolín-Colilla; Ramon M Pujol; Laia Curto-Barredo; Dulce Soto; Maribel García; Pilar Hernández; Ramon Gimeno; Ana M Giménez-Arnau Journal: Acta Derm Venereol Date: 2017-06-09 Impact factor: 4.437
Authors: Ivan Cherrez-Ojeda; Marcus Maurer; Jonathan A Bernstein; Emanuel Vanegas; Miguel Felix; German D Ramon; Luis Felipe Ensina; José Ignacio Larco Sousa; Edgar Emilio Matos Benavides; R Cardona Villa; P Latour Staffeld; Blanca María Morfin-Maciel; Jose Mori; Paul Wilches C; Valeria L Mata; Annia Cherrez Journal: World Allergy Organ J Date: 2019-02-23 Impact factor: 4.084
Authors: H Lapeere; M Baeck; A Stockman; V Sabato; M Grosber; M Moutschen; J Lambert; L Vandebuerie; L de Montjoye; H Rabijns; K Allewaert; R Schrijvers Journal: J Eur Acad Dermatol Venereol Date: 2019-08-19 Impact factor: 6.166
Authors: Amelia Licari; Sara Manti; Salvatore Leonardi; Domenico Minasi; Carlo Caffarelli; Fabio Cardinale; Michele Miraglia Del Giudice; Mauro Calvani; Giorgio Ciprandi; Gian Luigi Marseglia Journal: Acta Biomed Date: 2021-11-29